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Two recessive mammary tumour susceptibility loci,
SuprMam1 (for suppressor of mammary tumours) on
chromosome 7 (110-140 Mb) and SuprMam2 on chro-
mosome 2 (120-140MB) have been identified in the
BALB/c mouse strain in the Trp53+/- mouse model of
spontaneous breast cancer [1]. We studied mammary
gland morphology and expression levels of potential
candidate genes in SM09 congenic mice (BALB/c Supr-
Mam loci in C57BL/6 background) in comparison to
parental strains, to identify the genes within the Supr-
Mam loci that might be responsible for higher cancer
susceptibility in BALB/c mice.
We analysed mammary gland wholemounts for differ-
ences in their basic morphology. The average of ductal
branch count per 4x field of view was, BALB/c (diestrus)
=171, BALB/c (estrus) =173, C57BL/6 (diestrus) =43,
C57BL/6 (estrus) =38, SM09 (diestrus) =29 and SM09
(estrus) =23. According to these results, even though
there is a significant difference between the numbers of
ductal branches between the two parental strains BALB/
c and C57BL/6 (estrus:p=0.002, diestrus:p=0.027), there
is no significant difference between congenic (SM09)
and control (C57BL/6) mice during either estrus
(p=0.164) or diestrus (p=0.299) stages at 12 months of
age. A similar pattern was observed for total epithelial
area. This suggests that BALB/c SuprMam alleles alone
do not contribute significantly to the morphological dif-
ferences of the parental strains.
The tumour suppressor DMBT1 (deleted in malignant
brain tumors) has previously been identified as a
candidate modifier gene within SuprMam1 (1). Using
semi-quantitative RT-PCR, Dmbt1 mRNA was found to
be significantly lower in mammary glands of susceptible
BALB/c mice when compared to C57BL/6, while SM09
congenic mice had similar levels to the control C57BL/6
mice. This indicates that the lower level of Dmbt1
expression in BALB/c mice must be due to transcrip-
tional factor differences outside the region, which is not
present in SM09 congenics.
Using Affymetrix data comparing T cell gene expres-
sion across 5 different mouse strains, Cyp2r1,am a j o r
vitamin D hydroxylase, was identified as another poten-
tial candidate gene in SuprMam1. Plasma 25(OH)D
levels were measured in SM09 and control mice to
detect the effect of the different Cyp2r1 alleles. The
plasma levels of 25(OH)D were 20% higher in SM09
mice compared to control mice (control= 49.71 nM/L,
SM09= 59.44 nM/L). Surprisingly, however, this is the
opposite of what is expected based on the association of
CYP2R1 expression and cancer susceptibility in human
populations.
With these results, we are able to rule out two impor-
tant candidate genes, DMBT1 and CYP2R1, from being
responsible for the higher susceptibility of SuprMam
loci. In order to confirm these results, and also to iden-
tify the possible involvement of other selected candidate
genes, we aim to carry out transcriptional profiling on
mammary glands of SM09 congenic and control mice.
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